Last reviewed · How we verify

Purethal Birch immunotherapy

Medical University of Silesia · Phase 3 active Small molecule

Purethal Birch is an allergen immunotherapy that desensitizes the immune system to birch pollen allergens through gradual exposure.

Purethal Birch is an allergen immunotherapy that desensitizes the immune system to birch pollen allergens through gradual exposure. Used for Birch pollen-induced allergic rhinitis and/or allergic asthma.

At a glance

Generic namePurethal Birch immunotherapy
Also known asallergen specific immunotherapy
SponsorMedical University of Silesia
Drug classAllergen immunotherapy
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

This immunotherapy works by administering increasing doses of birch pollen allergen extract to induce immune tolerance and shift the immune response from IgE-mediated (allergic) to IgG-mediated (protective) antibodies. Over time, this reduces allergic symptoms and the need for symptomatic medications in patients with birch pollen allergy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results